Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Highlights

A collection of news and information related to Genentech Inc. published by this site and its partners.

Sort By: Relevancy | Date | Type
Displaying items 1-12 of 63
» View latimes.com items only
    May 12, 2013 |Story| Los Angeles Times

  1. Bill would regulate 'biosimilar' drugs

    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs.
    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs. At stake is a...

    Tags: U.S. Senate Committee on Appropriations, Chemical Industry, Health and Medical Professionals, Amgen Inc., Imports

    2. Apr 19, 2013 |Story| Los Angeles Times

  2. Strategies for cutting the cost of prescription drugs

    When Maggie Heim had a recurrence of ovarian cancer about a year after her initial treatment, her oncologist suggested that she take what he believed could be a lifesaving drug. There was just one problem: Her insurer wouldn't pay for it.
    When Maggie Heim had a recurrence of ovarian cancer about a year after her initial treatment, her oncologist suggested that she take what he believed could be a lifesaving drug. There was just one problem: Her insurer wouldn't pay for it. The 59-year-...

    Tags: High Blood Pressure, Medicare, Chemical Industry, Drugs and Medicines, Trials

    3. Apr 25, 2013 |Story| Los Angeles Times

  3. HIV vaccine trial shut down

    In another major setback for efforts to develop an HIV vaccine, federal researchers have shut down a key clinical trial after an independent panel of safety experts determined that volunteers who got an experimental vaccine appeared to be slightly more...

    Tags: Chemical Industry, AIDS, Trials, Health Organizations, Allergies

    4. Apr 22, 2013 |Story| Los Angeles Times

  4. Major corporations backed inaugural festivities

    WASHINGTON — President Obama's second inaugural committee raised a little more than $43 million to put on the official festivities surrounding his January swearing-in, backed by major donations from some of the country's biggest corporations,...

    Tags: Politics, Barack Obama, Coca-Cola Co., Festive Events, Finance

    5. Mar 29, 2013 |Story| Los Angeles Times

  5. Remove Medicare's straitjacket

    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although raising the age of Medicare eligibility from 65 to 67 appears off the table, at least for now, the budget plan that Rep. Paul D. Ryan (R-Wis.) is proposing would shift a greater share of the program's growing costs to beneficiaries in the years to come.
    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although...

    Tags: U.S. Congress, Medicare, Chemical Industry, Macular Degeneration, Drugs and Medicines

    6. Mar 17, 2013 |Story| Los Angeles Times

  6. Battle over 'biosimilars'

    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called "biosimilars."
    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies...

    Tags: Biotechnology Industry, U.S. Congress, Chemical Industry, Drugs and Medicines, Crime, Law and Justice

    7. Mar 6, 2013 |Story| Los Angeles Times

  7. Facebook is about to redesign News Feed: Here's what to expect

    SAN FRANCISCO -- Facebook is rolling out a radical new redesign of News Feed, the biggest since it launched the feature in 2006.
    SAN FRANCISCO -- Facebook is rolling out a radical new redesign of News Feed, the biggest since it launched the feature in 2006. The giant social network plans to unveil the redesign at a press conference Thursday at its Menlo Park, Calif.,...

    Tags: Biotechnology Industry, Chemical Industry, Media Industry, Star Trek (movie, 2009), Advertising

    8. Jan 14, 2013 |Story| Los Angeles Times

  8. Inaugural fundraisers race to meet $50-million goal

    <span class="runtimeTopic">WASHINGTON</span> &mdash; With less than a week to go before President Obama is sworn in for his second term, fundraisers for the presidential inaugural committee were still working Monday to secure their goal of $50 million in private donations to finance the official festivities.
    WASHINGTON — With less than a week to go before President Obama is sworn in for his second term, fundraisers for the presidential inaugural committee were still working Monday to secure their goal of $50 million in private donations to finance the...

    Tags: Federal Election Commission, United Therapeutics Corp., Barack Obama, Arts and Culture, Economy, Business and Finance

    9. Jan 30, 2012 |Story| Los Angeles Times

  9. New Avastin tests add to confusion over use in breast cancer

    In November, following an emotional public hearing some months earlier, the Food and Drug Administration withdrew approval for the cancer drug Avastin for patients with metastatic breast cancer &mdash; the late-stage, incurable form of the disease. The reason: emerging evidence that the drug does not prolong life and also that it's been linked to serious side effects.
    In November, following an emotional public hearing some months earlier, the Food and Drug Administration withdrew approval for the cancer drug Avastin for patients with metastatic breast cancer — the late-stage, incurable form of the disease. The...

    Tags: High Blood Pressure, Mouth, Cancer, Medical Specialization, Health Organizations

    10. Apr 18, 2012 |Story| Los Angeles Times

  10. Roche won't extend $6.8 billion bid for San Diego's Illumina

    Swiss drugmaker Roche will not extend its hostile $6.8-billion bid for Illumina Inc. after the San Diego biotech company&rsquo;s shareholders rejected Roche&rsquo;s attempts to appoint new board members.
    Swiss drugmaker Roche will not extend its hostile $6.8-billion bid for Illumina Inc. after the San Diego biotech company’s shareholders rejected Roche’s attempts to appoint new board members. Roche’s current offer of $51 per Illumina...

    Tags: Diabetes, Economy, Business and Finance, Shareholders, Companies and Corporations, Cancer

    11. Nov 15, 2011 | Los Angeles Times

  11. Disney CEO Iger joins Apple board; Levinson named chairman

    Technology
    In the first change to Apple's boardroom since the death of Steve Jobs last month, the company announced that Walt Disney Co. President and Chief Executive Robert Iger will be the Cupertino electronics maker's newest board member....
    12. Jun 28, 2011 | Los Angeles Times

  12. Avastin: There's the truth and then there's the politics behind the cancer drug [The conversation]

    Opinion L.A.
    Avastin: The FDA goes up against drug manufacturer Genentech with regards to the late-stage cancer drug....
 1  2 3 4 5 6 • Next >
Original site for Genentech Inc. topic gallery.
Advertisement
Loading...
 
 

Date:

Credit:

User-submitted

Tags:

Rate:
Sending...

E-mail this photo

Error: malformed email address(es)
Both "from" and "recipient" email fields are required.

Recipient E-mail Addresses

(up to 3, separated by commas) Send me a copy.

From:

e-mail | buy this photo | link to photo
Genentech Inc. Photos
Some firms seek to make "biosimilar" drugs that would p...
(April 25, 2013)
Bill would regulate &#8216;biosimilar&#8217; drugs
A sign is displayed in front of the Genentech headquart...
(December 13, 2012)
A sign is displayed in front of the Genentech headquarters July 14, 2008 in South San Francisco, California. This company relied on the popularity of its cancer drug Avastin to boost profits.
Dr. Jeffrey Bloss has joined Astellas US LLC as vice pr...
(November 28, 2012)
Dr. Jeffrey Bloss, vice president of scientific and medical affairs, Astellas US LLC
 » All 4 Genentech Inc. photos